Human Data Logo
NBDC HumanDB
NBDC Research ID:hum0362-v1
Release info
Latest

Research title

The study on genomic profiling using clinical specimens (tissue, blood, etc.) form patients with lung and thymic tumors

Research overview

Aims: This study has following four objectives 1) We identify driver mutations, classify the disease by gene profiling, and evaluate biomarkers that predict treatment efficacy and genomic changes during recurrence or metastasis. 2) We identify biomarkers that predict therapeutic efficacy and toxicity by analyzing polymorphisms of genes related to pharmacokinetics and pharmacology in non-tumor tissues and genetic mutations related to familial tumors and by performing association analysis between germline gene profiling and clinical information. 3) We compare "Clinical Liquid Sequencing" using plasma-derived free DNA with tissue biopsy ("Clinical Sequencing") to evaluate its efficacy. 4) In thymic tumors, we will examine immune cell profiling. The relationship between thymic tumors and autoimmune diseases will also be examined.

Methods: RNA-seq analysis

Targets: 98 thymoma cases (97 thymoma samples and one normal thymus sample)

Datasets

Dataset ID
Access type
Type of data
Release date
JGAD000672Controlled-access (Type I)NGS (RNA-seq)2025-04-10

Data provider

    Principal investigator
    Shinichi Yachida
    Name
    Cancer Genome Informatics, Osaka University

Research projects

Name
URL
The study on genomic profiling using clinical specimens (tissue, blood, etc.) from patients with lung and thymic tumors

Grants

Name
Title
Project number
KAKENHI Grant-in-Aid for Scientific Research (B)Metagenomic analysis of familial adenomatous polyposis and its implications for understanding the pathogenesis of colorectal cancer
  • JP20H033620
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Developmstent (AMED)Research aimed at elucidating alterations in the intestinal microenvironment associated with colorectal cancer development in high-risk individuals, and the development of personalized preventive strategies based on these findings
  • JP21ck0106546
Project for Cancer Research and Therapeutic Evolution, Japan Agency for Medical Research and Developmstent (AMED)Research and development aimed at predicting the occurrence of adverse effects associated with anticancer drugs through comprehensive analysis of the gut microbiota
  • JP21cm0106477
Research Program on the challenges of Global Health issues, Japan Agency for Medical Research and Developmstent (AMED)Investigation of infection-associated cancers conducted within the framework of the Japan-U.S. Medical Cooperation Program
  • JP20jk0210009
Project for Promotion of Cancer Research and Therapeutic Evolution, Japan Agency for Medical Research and Developmstent (AMED)Development of biomarkers for early detection and susceptibility assessment of young-onset colorectal cancer through comprehensive analysis of the intestinal microenvironment
  • JP22ama221404
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Developmstent (AMED)Collection and analysis of whole-genome sequencing data and clinical information on treatment-resistant gastrointestinal cancers, such as esophageal cancer, with the aim of facilitating drug development and establishing a nationwide infrastructure for genome-informed medical care in Japan
  • JP22ck0106690
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Developmstent (AMED)Advancement of preventive, diagnostic, and therapeutic approaches through comprehensive genomic analysis of rare malignancies, including sarcomas and brain tumors
  • JP21ck0106693
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Developmstent (AMED)Development of novel strategies for prevention, diagnosis, and treatment through comprehensive genomic analysis of rare cancers, including sarcomas and brain tumors
  • JP24ck0106877
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Developmstent (AMED)Implementation of advanced cancer precision medicine through the timely and accurate return of patient-specific data, including whole-genome information, alongside the development of novel therapeutics
  • JP24ck0106872
the National Cancer Center Research and Development Fund
  • 2023-A-06
Japan Health Research Promotion Bureau Research Fund
  • JH2022-B-01
Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University
    Joint Research Project of the Institute Medical Science, the University of Tokyo
      the Takeda Science Foundation
        the Yasuda Medical Foundation
          the Mitsubishi Foundation
            the Princess Takamatsu Cancer Research Fund
              Takara Bio Inc.

                Related publications

                Title
                DOI
                Dataset ID
                Characterizing the Tumor Immune Environment in Thymic Epithelial Tumors Using T-cell Receptor Repertoire Analysis and Gene Expression Profilinghttps://doi.org/10.1016/j.xjon.2025.03.008

                Controlled access users

                Principal Investigator
                Affiliation
                Country/Region
                Research title
                Period of data use
                Dataset ID
                No data